Upregulation of retinoic acid receptor-β by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways

Journal of Cellular Physiology

Volumn 211, Issue 3, 2007, Pages 803-815

  Grunt, Thomas W ^a   Tomek, Katharina ^a   Wagner, Renate ^a   Puckmair, Klaudia ^a   Kainz, Birgit ^a   Rünzler, Dominik ^b   Gaiger, Alexander ^a   Köhler, Gottfried ^b   Zielinski, Christoph C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHOXY)PHENYL]CROTONAMIDE; 3,5 DI TERT BUTYL ALPHA CYANO 4 HYDROXYTHIOCINNAMAMIDE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; ALPHA (3,5 DICHLOROBENZYLIDENE) 3 PYRIDYLACETONITRILE; EBE A22; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; GEFITINIB; HISTONE DEACETYLASE 1; HISTONE H3; HISTONE H4; MESSENGER RNA; RETINOIC ACID RECEPTOR BETA; RNA POLYMERASE II; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DNA METHYLATION; DRUG ACTIVITY; DRUG DNA BINDING; DRUG EFFECT; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, RETINOIC ACID; RNA PROCESSING, POST-TRANSCRIPTIONAL; TRANSCRIPTION, GENETIC; TYRPHOSTINS; UP-REGULATION;

EID: 34247584469     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20990     Document Type: Article

References (44)

1. Altucci L, Gronemeyer H. 2001. The promise of retinoids to fight against cancer. Nat Rev Cancer 1:181-193.
2. Banerjee R, Rachid Z, Qiu Q, McNamee JP, Tari AM, Jean-Claude BJ. 2004. Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line. Br J Cancer 91:1066-1073.
3. Bouey-Bencteux E, Loison C, Pommery N, Houssin R, Henichart JP. 1998. Synthesis and antiproliferative properties of 4-aminoquinazoline derivatives as inhibitors of EGF receptor-associated tyrosine kinase activity. Anti-Cancer Drug Des 13:893-922.
4. Bovenzi V, Momparler RL. 2001. Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol 48:71-76.
5. Bovenzi V, Le NL, Cote S, Sinnett D, Momparler LF, Momparler RL. 1999. DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2′-deoxycytidine. Anticancer Drugs 10:471-476.
6. Brahimi F, Rachid Z, Qiu Q, McNamee JP, Tari AM, Jean-Claude BJ. 2004. Multiple mechanisms of action of ZR2002 in human breast cancer cells: A novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA. Int J Cancer 112:484-491.
7. Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HD, Fry DW, Kraker AJ, Denny WA. 1996. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7- dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem 39:267-276.
8. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD. 2001. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93:691-699.
9. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. 1999. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107.
10. Cappuzzo F, Gregore V, Rossi E, Cancellieri A, Magrini E, Paties CT, Ceresoli G, Lombardo L, Bartolini S, Calandri C, de Rosa M, Villa E, Crino L 2003. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21:2658-2663.
11. Chambon P. 1996. A decade of molecular biology of retinoic acid receptors. FASEB J 10:940-954.
12. Cote S, Momparler RL. 1997. Activation of the retinoic acid receptor beta gene by 5-aza-2′-deoxycytidine in human DLD-1 colon carcinoma cells. Anticancer Drugs 8:56-61.
13. Cote S, Sinnett D, Momparler RL. 1998. Demethylation by 5-aza-2′-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs 9:743-750.
14. Ferrara F, Fazi F, Bianchii A, Padula F, Gelmetti V, Minucci S, Mancini M, Pelicci PG, Lo Coco F, Nervi C. 2001. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61:2-7.
15. Fry DW, Kraker AJ, McMichael A, Ambrose LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ. 1994. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265:1093-1095.
16. Goossens J-F, Bouey-Bencteux E, Houssin R, Henichart JP, Colson P, Houssier C, Laine W, Baldeyrou B, Bailly C. 2001. DNA interaction of the tyrosine protein kinase inhibitor PD153035 and its N-methyl analogue. Biochemistry 40:4663-4671.
17. Grunt TW. 2003. Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells. Cancer Lett 189:147-156.
18. Grunt TW, Dittrich E, Offterdinger M, Schneider SM, Dittrich C, Huber H. 1998. Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Brit J Cancer 78:79-87.
19. Grunt TW, Puckmair K, Tomek K, Kainz B, Gaiger A. 2005. An EGF receptor inhibitor induces RAR-β expression in breast and ovarian cancer cells. Biochem Biophys Res Commun 329:1253-1259.
20. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826.
21. Hynes N. 2000. Tyrosine kinase signalling in breast cancer. Breast Cancer Res 2:154-157.
22. Kastner P, Mark M, Ghyselinck N, Krezel W, Dupe V, Grondona JM, Chambon P. 1997. Genetic evidence that the retinoid signal is transduced by heterodimeric RXR/RAR functional units during mouse development. Development 124:313-326.
23. Lee X, Si SP, Tsou HC, Peacocke M. 1995. Cellular aging and transformation suppression: A role for retinoic acid receptor beta 2. Exp Cell Res 218:296-304.
24. Levitzki A, Gazit A. 1995. Tyrosine kinase inhibition: An approach to drug development. Science 267:1782-1788.
25. Lin F, Xiao D, Kolluri SK, Zhang X. 2000. Unique anti-activator protein-1 activity of retinoic acid receptor beta. Cancer Res 60:3271-3280.
26. Liu Y, Lee M, Wang H-G, Li Y, Hashimoto Y, Klaus M, Reed JC, Zhang X-K. 1996. Retinoic acid receptor β mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol 16:1138-1149.
27. Mendelsohn J, Baselga J. 2000. The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-6565.
28. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. 2003. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment. Endocr Relat Cancer 10:1-21.
29. Offterdinger M, Schneider SM, Huber H, Grunt TW. 1998. Retinoids control the expression of c-erbB receptors in breast cancer cells. Biochem Biophys Res Commun 251:907-913.
30. Offterdinger M, Schneider SM, Huber H, Grunt TW. 1999. Expression of c-erbB-4/HER4 is regulated in T47D breast carcinoma cells by retinoids and vitamin D3. Biochem Biophys Res Commun 258:559-564.
31. Offterdinger M, Schneider SM, Grunt TW. 2003. Heregulin and retinoids synergistically induce branching morphogenesis of breast cancer cells cultivated in 3D collagen gels. J Cell Physiol 195:260-275.
32. Rachid Z, Brahimi F, Domarkas J, Jean-Claude BJ. 2005. Synthesis of half-mustard combi-molecules with fluorescence properties: Correlation with EGFR status. Bioorg Med Chem Lett 15:1135-1138.
33. Rewcastle GW, Denny WA, Bridges AJ, Zhou H, Cody DR, McMichael A, Fry DW. 1995. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J Med Chem 38:3482-3487.
34. Schneider SM, Offterdinger M, Huber H, Grunt TW. 1999. Involvement of nuclear steroid/retinoid/thyroid receptors and of protein kinases in the regulation of growth and of c-erbB and retinoic acid receptor expression in MCF-7 breast cancer cells. Breast Cancer Res Treat 58:171-181.
35. Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S, Sacchi N. 2000. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. Oncogene 19:1556-1563.
36. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, Toma S, Nicolo G, Sacchi N. 2002. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 62:2455-2461.
37. Slichenmyer WJ, Fry DW. 2001. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 28:67-79.
38. Swisshelm K, Ryan K, Lee X, Tsou HC, Peacocke M, Sager R. 1994. Downregulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ 5:133-141.
39. Tighe AP, Talmage DA. 2004. Retinoids arrest breast cancer cell proliferation: Retinoic acid selectively reduces the duration of receptor tyrosine kinase signaling. Exp Cell Res 301:147-157.
40. Virmani AK, Rathi A, Zoechbauer-Mueller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gaidar AF. 2000. Promoter methylation and silencing of the retinoic acid receptor β gene in lung carcinomas. J Natl Cancer Inst 92:1303-1307.
41. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. 2002. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749-5754.
42. Widschwendter M, Berger J, Daxenbichler G, Muller-Holzner E, Widschwendter A, Mayr A, Marth C, Zeimet AG. 1997. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res 57:4158-4161.
43. Widschwendter M, Berger J, Hermann M, Muller HM, Amberger A, Zeschnigk M, Widschwendter A, Abendstein B, Zeimet AG, Daxenbichler G, Marth C. 2000. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst 92:826-832.
44. Yang-Yen HF, Zhang X-K, Graupner G, Tzukerman M, Sakamoto B, Karin M, Pfahl M. 1991. Antagonism between retinoic acid receptors and AP-1: Implications for tumor promotions and inflammation. New Biol 3:1206-1219.